{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:27:06Z","timestamp":1794090426723,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Zaire<\/jats:italic>\n                    <jats:italic>ebolavirus<\/jats:italic>\n                    (EBOV) is a highly pathogenic filovirus which can result in Ebola\u00a0virus disease (EVD); a serious medical condition that presents as flu like symptoms but then often leads to more serious or fatal outcomes. The 2013\u201316 West Africa epidemic saw an unparalleled number of cases. Here we show characterisation and identification of T cell epitopes in surviving patients from Guinea to the EBOV glycoprotein. We perform interferon gamma (IFN\u03b3) ELISpot using a glycoprotein peptide library to identify T cell epitopes and determine the CD4\n                    <jats:sup>+<\/jats:sup>\n                    or CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell component response. Additionally, we generate data on the T cell phenotype and measure polyfunctional cytokine secretion by these antigen specific cells. We show candidate peptides able to elicit a T cell response in EBOV survivors and provide inferred human leukocyte antigen (HLA) allele restriction. This data informs on the long-term T cell response to Ebola virus disease and highlights potentially important immunodominant peptides.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-21411-0","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T11:02:53Z","timestamp":1613818973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013\u201316 West Africa epidemic"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-528X","authenticated-orcid":false,"given":"T. R. W.","family":"Tipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Bore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9481-0079","authenticated-orcid":false,"given":"A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sarfas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-431X","authenticated-orcid":false,"given":"S.","family":"Longet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9827-9836","authenticated-orcid":false,"given":"K.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0230","authenticated-orcid":false,"given":"S.","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-2180","authenticated-orcid":false,"given":"M.","family":"Carrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Kond\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"21411_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.15585\/mmwr.su6503a3","volume":"65","author":"BA Dahl","year":"2016","unstructured":"Dahl, B. A. et al. CDC\u2019s response to the 2014-2016 ebola epidemic - Guinea, Liberia, and Sierra Leone. MMWR Suppl. 65, 12\u201320 (2016).","journal-title":"MMWR Suppl."},{"key":"21411_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","volume":"374","author":"K Ewer","year":"2016","unstructured":"Ewer, K. et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N. Engl. J. Med. 374, 1635\u20131646 (2016).","journal-title":"N. Engl. J. Med."},{"key":"21411_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857\u2013866 (2015).","journal-title":"Lancet"},{"key":"21411_CR4","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","volume":"220","author":"SA Halperin","year":"2019","unstructured":"Halperin, S. A. et al. Immunogenicity, lot consistency, and extended safety of rVSVDeltaG-ZEBOV-GP Vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults. J. Infect. Dis. 220, 1127\u20131135 (2019).","journal-title":"J. Infect. Dis."},{"key":"21411_CR5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/infdis\/jix189","volume":"215","author":"SA Halperin","year":"2017","unstructured":"Halperin, S. A. et al. Six-month safety data of recombinant vesicular stomatitis virus-zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J. Infect. Dis. 215, 1789\u20131798 (2017).","journal-title":"J. Infect. Dis."},{"key":"21411_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"AM Henao-Restrepo","year":"2017","unstructured":"Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 389, 505\u2013518 (2017).","journal-title":"Lancet"},{"key":"21411_CR7","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","volume":"381","author":"S Mulangu","year":"2019","unstructured":"Mulangu, S. et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 381, 2293\u20132303 (2019).","journal-title":"N. Engl. J. Med."},{"key":"21411_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer, K. J. et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat. Commun. 4, 2836 (2013).","journal-title":"Nat. Commun."},{"key":"21411_CR9","unstructured":"Agency, E. M. New vaccine for prevention of Ebola virus disease recommended for approval in the European Union. https:\/\/www.ema.europa.eu\/en\/news\/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union (2020)."},{"key":"21411_CR10","doi-asserted-by":"publisher","first-page":"14189","DOI":"10.1128\/JVI.79.22.14189-14196.2005","volume":"79","author":"GG Olinger","year":"2005","unstructured":"Olinger, G. G. et al. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins. J. Virol. 79, 14189\u201314196 (2005).","journal-title":"J. Virol."},{"key":"21411_CR11","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.2447","volume":"17","author":"NJ Sullivan","year":"2011","unstructured":"Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128\u20131131 (2011).","journal-title":"Nat. Med."},{"key":"21411_CR12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1073\/pnas.1209591110","volume":"110","author":"A Marzi","year":"2013","unstructured":"Marzi, A. et al. Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110, 1893\u20131898 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21411_CR13","doi-asserted-by":"publisher","unstructured":"Thom, R. et al. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(20)30736-2 (2020).","DOI":"10.1016\/S1473-3099(20)30736-2"},{"key":"21411_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature17949","volume":"533","author":"P Ruibal","year":"2016","unstructured":"Ruibal, P. et al. Unique human immune signature of Ebola virus disease in Guinea. Nature 533, 100\u2013104 (2016).","journal-title":"Nature"},{"key":"21411_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.55","volume":"7","author":"C Agrati","year":"2016","unstructured":"Agrati, C. et al. Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection. Cell Death Dis. 7, e2164 (2016).","journal-title":"Cell Death Dis."},{"key":"21411_CR16","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1073\/pnas.1502619112","volume":"112","author":"AK McElroy","year":"2015","unstructured":"McElroy, A. K. et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl Acad. Sci. USA 112, 4719\u20134724 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"21411_CR17","doi-asserted-by":"publisher","unstructured":"Sakabe, S. et al. Analysis of CD8(+) T cell response during the 2013\u20132016 Ebola epidemic in West Africa. Proc. Natl Acad. Sci. U. S. A. https:\/\/doi.org\/10.1073\/pnas.1806200115 (2018).","DOI":"10.1073\/pnas.1806200115"},{"key":"21411_CR18","doi-asserted-by":"publisher","first-page":"e2302","DOI":"10.21769\/BioProtoc.2302","volume":"7","author":"MN Wykes","year":"2017","unstructured":"Wykes, M. N. & Renia, L. ELISPOT assay to measure peptide-specific IFN-\u03b3 production. Bio-Protoc. 7, e2302 (2017).","journal-title":"Bio-Protoc."},{"key":"21411_CR19","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.celrep.2019.10.105","volume":"29","author":"J Powlson","year":"2019","unstructured":"Powlson, J. et al. Characterization of antigenic MHC-class-I-restricted T cell epitopes in the glycoprotein of ebolavirus. Cell Rep. 29, 2537\u20132545 e2533 (2019).","journal-title":"Cell Rep."},{"key":"21411_CR20","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/eji.201343751","volume":"43","author":"YD Mahnke","year":"2013","unstructured":"Mahnke, Y. D., Brodie, T. M., Sallusto, F., Roederer, M. & Lugli, E. The who\u2019s who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 43, 2797\u20132809 (2013).","journal-title":"Eur. J. Immunol."},{"key":"21411_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-4939-6548-9_3","volume":"1514","author":"E Lugli","year":"2017","unstructured":"Lugli, E., Zanon, V., Mavilio, D. & Roberto, A. FACS Analysis of Memory T Lymphocytes. Methods Mol. Biol. 1514, 31\u201347 (2017).","journal-title":"Methods Mol. Biol."},{"key":"21411_CR22","first-page":"287","volume":"215","author":"C Dahlke","year":"2017","unstructured":"Dahlke, C. et al. Comprehensive characterization of cellular immune responses following Ebola virus infection. J. Infect. Dis. 215, 287\u2013292 (2017).","journal-title":"J. Infect. Dis."},{"key":"21411_CR23","doi-asserted-by":"publisher","unstructured":"Davis, C. et al. Post-exposure prophylaxis with rVSV-ZEBOV following exposure to a patient with Ebola virus disease relapse in the UK: an operational, safety and immunogenicity report. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciz1165 (2019).","DOI":"10.1093\/cid\/ciz1165"},{"key":"21411_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.micpath.2019.05.010","volume":"132","author":"B Ahmad","year":"2019","unstructured":"Ahmad, B., Ashfaq, U. A., Rahman, M. U., Masoud, M. S. & Yousaf, M. Z. Conserved B and T cell epitopes prediction of Ebola virus glycoprotein for vaccine development: an immuno-informatics approach. Micro. Pathog. 132, 243\u2013253 (2019).","journal-title":"Micro. Pathog."},{"key":"21411_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cell.2015.12.044","volume":"164","author":"H Wang","year":"2016","unstructured":"Wang, H. et al. Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell 164, 258\u2013268 (2016).","journal-title":"Cell"},{"key":"21411_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fimmu.2012.00037","volume":"3","author":"EB Compeer","year":"2012","unstructured":"Compeer, E. B., Flinsenberg, T. W., van der Grein, S. G. & Boes, M. Antigen processing and remodeling of the endosomal pathway: requirements for antigen cross-presentation. Front Immunol. 3, 37 (2012).","journal-title":"Front Immunol."},{"key":"21411_CR27","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.ppat.1001098","volume":"6","author":"JR Francica","year":"2010","unstructured":"Francica, J. R. et al. Steric shielding of surface epitopes and impaired immune recognition induced by the Ebola virus glycoprotein. PLoS Pathog. 6, e1001098 (2010).","journal-title":"PLoS Pathog."},{"key":"21411_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","volume":"35","author":"Y Zhou","year":"2015","unstructured":"Zhou, Y. & Sullivan, N. J. Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr. Opin. Immunol. 35, 131\u2013136 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"21411_CR29","doi-asserted-by":"publisher","unstructured":"Bowyer, G. et al. Activation-induced markers detect vaccine-specific CD4(+) T cell responses not measured by assays conventionally used in clinical trials. Vaccines (Basel) 6, https:\/\/doi.org\/10.3390\/vaccines6030050 (2018).","DOI":"10.3390\/vaccines6030050"},{"key":"21411_CR30","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.vaccine.2017.02.038","volume":"35","author":"T Ford","year":"2017","unstructured":"Ford, T. et al. Cryopreservation-related loss of antigen-specific IFNgamma producing CD4(+) T-cells can skew immunogenicity data in vaccine trials: lessons from a malaria vaccine trial substudy. Vaccine 35, 1898\u20131906 (2017).","journal-title":"Vaccine"},{"key":"21411_CR31","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"21411_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nm.4241","volume":"23","author":"L Gattinoni","year":"2017","unstructured":"Gattinoni, L., Speiser, D. E., Lichterfeld, M. & Bonini, C. T memory stem cells in health and disease. Nat. Med. 23, 18\u201327 (2017).","journal-title":"Nat. Med."},{"key":"21411_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","volume":"29","author":"JE Ledgerwood","year":"2010","unstructured":"Ledgerwood, J. E. et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29, 304\u2013313 (2010).","journal-title":"Vaccine"},{"key":"21411_CR34","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley, D. A. et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat. Med. 20, 1126\u20131129 (2014).","journal-title":"Nat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21411-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:51:30Z","timestamp":1669960290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-21411-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["21411"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-21411-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"29 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1153"}}